# Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

> **NCT01738087** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 30 (actual)

## Conditions studied

- Asthmatic

## Interventions

- **DRUG:** NEXThaler 100/6 mcg DPI
- **DRUG:** Flixotide Accuhaler 500 mcg
- **DRUG:** NEXThaler 200/6 mcg DPI
- **DRUG:** NEXThaler placebo

## Key facts

- **NCT ID:** NCT01738087
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01738087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01738087, "Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01738087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*